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Introduction
Unfractionated heparin (UFH) has been used as an anticoagulant and antithrombotic agent since the early 1940s, which makes this glycosaminoglycan-based drug one of the oldest biologics still in use [1] [2] [3] . The anticoagulant mechanism of UFH relies on the inactivation of several enzymes of the coagulation system, especially thrombin (activated factor II [FIIa] ) and activated FX (FXa), through the potentiation of antithrombin (AT) and heparin cofactor II [1] . Even with the introduction of low molecular weight heparins (LMWHs) and the direct oral anticoagulants for the prophylaxis and treatment of thromboembolism [4] , UFH is still indispensable in cardiovascular surgeries that demand extracorporeal circulation and during renal dialysis sessions [5] . At the end of these procedures or in cases of overdose, the remnant UFH is always neutralized with protamine sulfate or chloride, which promptly reverses the low-coagulant state of the patient in a controlled manner [6] .
Protamine (Fig. 1A) is composed of four arginine-rich peptide chains purified from the sperm or testes of salmon [7] . UFH neutralization by protamine operates through the formation of an insoluble UFH-protamine complex that immediately stops the anticoagulant effect of the UFH [8] . Previous studies have shown that UFH has more affinity for protamine than LMWHs, and that the neutralization acts more effectively on AT inhibition of FIIa than on AT inhibition of FXa [9] [10] [11] . The clinical dose of both protamine sulfate and protamine chloride recommended by the manufacturers is 1 mg (dry weight basis) to neutralize not less than 100 International Units (IU) of UFH [12, 13] .
Pharmaceutical UFH is currently prepared from porcine or bovine intestinal mucosa [14] [15] [16] [17] ; however, these preparations yield UFH products with different anticoagulant potencies and disaccharide proportions. UFH from porcine intestine (HPI) has anticoagulant activity of 180 IU mg À1 , whereas preparations from bovine intestine (HBI) have approximately half of this anticoagulant activity (~100 IU mg À1 ) [17] . The differences in the anticoagulant potencies of HPI and HBI are directly related to their structural dissimilarities [14, 17] . HPI is mainly composed of homogeneous chains enriched in N,6-disulfated a-glucosamine units; on the other hand, HBI is a heterogeneous mixture, containing parts of the chains with high proportions of N-sulfated a-glucosamine (Fig. 1B) . Such structural differences can be easily observed in 1D 1 H-nuclear magnetic resonance (NMR) spectra of HPI and HBI (Fig. 1C) . Because of these noticeable chemical and pharmacological differences, UFHs from porcine and bovine intestine were recently considered to be distinct drugs, which led to the publication of separate monographs for HPI and HBI by the Brazilian Pharmacopeia [18] , a tendency that will be followed by other pharmacopeias worldwide.
UFHs from different animal sources require different quantities of protamine to be effectively neutralized [19] . This became clear when several episodes of postsurgical bleeding were reported in Brazilian hospitals after the use of protocols designed for protamine neutralization of HPI in procedures employing HBI [20, 21] . HBI preparations were then withdrawn from clinical use in Brazil, and HPI became the only UFH product available. This serious medical event revealed the risk of using a single protocol for protamine neutralization of UFHs from different animal sources. Except for Brazil (temporarily withdrawn), Argentina, India, and some Islamic countries, where HBI remains available, the rest of the world employs HPI products [16] ; however, the US Food and Drug Administration (FDA) recommended the diversification of the UFH supply chain through the reintroduction of HBI [16] . Therefore, it is possible that two distinct UFH products (HPI and HBI), with different protamine-neutralization profiles, will soon be simultaneously available for clinical use worldwide.
Most of the research on protamine neutralization of UFHs is based on clinical cases of patients undergoing procedures involving heparinization or in vitro and ex vivo assessments of their anticoagulant activities after the neutralization reactions [22] [23] [24] . It has already been demonstrated that the anticoagulant activity of HPI is neutralized more effectively than that of HBI [19] ; however, the chemical aspects leading to these different neutralization profiles have not been clearly elucidated so far. In the present study, we performed in-depth chemical and pharmacological assessments of the neutralization of UFHs from different animal sources (HPI and HBI) by protamine chloride (referred to as protamine henceforth). We first evaluated the neutralization of the different UFHs by protamine on the basis of the loss of their anticoagulant potencies with in vitro and ex vivo assays, and by quantifying their bleeding tendencies, before and after protamine administration, with an in vivo experimental model. Then, we assessed the chemical aspects of the neutralization of HPI and HBI by protamine by using two different approaches: (i) solution 1D 1 H-NMR, to observe how the monosaccharide units of both intact HPI and HBI, as well of two fractions with different disaccharide compositions isolated from HBI, behave during the complexation with protamine; and (ii) electrospray ionization high-resolution mass spectroscopy (ESI-HRMS), to determine whether the different peptide components of protamine complex preferentially with these different UFHs (Fig. 1D) . In view of the imminent reintroduction of HBI, as recommended by the FDA, the development of a protocol with precise instructions for the neutralization of this UFH by protamine is mandatory to avoid bleeding accidents such as those experienced in Brazil.
Materials and methods
Commercial batches of pharmaceutical-grade HBI and HPI (six of each) were employed in the assays. These batches are representatives selected from 210 batches of HBI and 150 batches of HPI produced and/or formulated by different Brazilian pharmaceutical companies that have had quality assessments fully or partially performed by our laboratory. Higher-sulfated and lower-sulfated fractions isolated from HBI were prepared as previously described [25] . Protamine chloride was used instead of protamine sulfate (which is more commonly used worldwide) because it is the only commercial preparation available for clinical use in Brazil. The UFHs were first analyzed by the use of activated partial thromboplastin time (APTT) assays with human plasma in an Amelung KC4A coagulometer (Heinrich Amelung GmbH, Lemgo, Germany ) were titrated with increasing concentrations of protamine (0-2 mg mL À1 ), and then centrifuged (1000 g, 10 min); the residual UFH present in the supernatant was quantified by measuring the hexuronic acid content [24] .
Ex vivo and in vitro neutralization of anti-FXa and anti-FIIa activities of the UFHs by protamine were assessed by measuring the hydrolysis of specific chromogenic substrates as previously described [14, 17] . In the ex vivo experiments, HPI or HBI (200 IU kg À1 ) was administered intravenously to rats, and increasing concentrations of protamine were then added to the plasmas collected from the rats, which were subsequently incubated with the purified proteins to evaluate the neutralization of their anti-FIIa and anti-FXa activities. Anti-FIIa and FXa in vitro assays were performed by incubating 2 nM of these purified proteins with 0.04 IU mL À1 of each UFH, AT (10 nM), and protamine (0.05-1 lg mL
À1
). After 60 s, the remaining FXa or FIIa activities were determined by the use of a chromogenic substrate, as described previously [14] . The bleeding effect assays were performed by intravenously administering 2 mg kg À1 (body weight) HPI or 4 mg kg À1 HBI (both 400 IU mg kg À1 ) alone or followed (5 min later) by protamine (4 mg kg À1 , intravenous) to Wistar rats. The blood loss was evaluated as previously described [14] , at 22°C, and in rats with a body weight of 200 g, in order to reduce the blood loss variations during the assays. The UFHs were analyzed with affinity chromatography employing a column (1 mL) filled with Sephadex CL4B (Sigma-Aldrich, St. Louis, MO, USA) coupled to protamine, linked to an HPLC system (Shimadzu, Tokyo, Japan); the coupling procedure was performed according to the manufacturer's instructions [26] . The UFHs (1 mg of each) were eluted from the column with a continuous NaCl gradient (0-3 M) and monitored by absorbance (215 nm) and conductivity, as described elsewhere [27] . 1D 1 H-NMR spectra of the UFHs titrated with protamine were recorded with a DRX 800-MHz spectrometer (Bruker, Billerica, MA, USA) with a triple-resonance probe as previously described [17, 26, 28] . Intact HPI and HBI or the highersulfated and lower-sulfated fractions isolated from HBI (5 mg of each) were dissolved in 99.9% deuterium oxide (0.5 mL) and titrated with protamine (1-9 mg). All spectra were recorded at 35°C with HOD suppression by presaturation, as described elsewhere [17, 26, 28] . Each spectrum was acquired by recording 64 scans with an interscan delay of 1 s. Chemical shifts are displayed relative to the external standard trimethyl-silylpropionic acid at 0 p.p.m. for 1 H. ESI-HRMS spectra of protamine after complexation with the UFHs were recorded with a Q Exactive-Plus Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher, Waltham, MA, USA). Briefly, HPI and HBI (10 lg of each) were incubated with 50 lg of protamine previously cleaned by use of a desalting column (GE Healthcare, Chicago, IL, USA) in 0.01 M phosphatebuffered saline, pH 7.4 (200 lL), and then centrifuged (1000 g, 10 min). The supernatants containing residual protamine (80 lL) and 1.5 lg (20 lL) of the internal standard peptide Met-Arg-Phe-Ala from Sigma-Aldrich were directly infused into the Orbitrap set-up with a sheath gas flow rate of 40 arbs, a spray voltage of 5 kV, a capillary temperature of 250°C, an S-lens radiofrequency level of 80, and in-source collision-induced dissociation of 40 eV. Spectra were obtained in a mass range between 500 m/z and 550 m/z with an automatic control gain of 5 9 10 6 and 20 ms of maximum injection time. All of the statistical analyses were performed with ORIGIN 8 (Originlab, Northampton, MA, USA).
Results and discussion
Neutralization of HPI and HBI by protamine operates on a mass basis HPI and HBI have different anticoagulant potencies, as demonstrated with different analytical approaches by different research groups [e.g. [14] [15] [16] [17] [18] [19] . To confirm these differences, we assessed the anticoagulant potencies of commercial preparations of HPI and HBI in relation to the 6th International Standard of UFH (lot 07/328; NIBSC), prepared from porcine intestine, by using an APTT clotting assay with human plasma (Fig. 2A) , by increasing the quantities of HBI to ⁓ 122% per dose, the anticoagulant potencies of HBI and HPI measured with APTT assays were similar, confirming that higher doses of HBI are necessary to achieve the same anticoagulant potency as that of HPI (Fig. 2B) .
After confirming that HBI has lower anticoagulant activity than HPI, we evaluated how these different UFHs are neutralized by protamine by evaluating the loss of their anticoagulant activities with APTT assays (Fig. 2C) . We performed the assays by using doses of HPI and HBI with the same anticoagulant potency (0.25 IU mL À1 ) and hence with different masses (1.25 lg mL À1 and 2.77 lg mL À1 HPI and HBI, respectively). HBI requires significantly higher (P < 0.05) doses of protamine than HPI to be completely neutralized (1.27 mg mL À1 versus 0.76 mg mL À1 ). The higher dose of protamine needed to fully neutralize HBI is possibly related to the higher quantity of this UFH employed in the assays, indicating that the neutralization of these UFHs by protamine operates on a mass basis though their different anticoagulant potencies and disaccharide compositions. To confirm whether the different UFHs interact with protamine on a mass/mass basis, we also employed an alternative approach: a precipitation assay. In this assay, fixed quantities of both HPI and HBI (1 mg mL À1 ) were titrated with increasing concentrations of protamine (0-2 mg mL À1 ), and the residual UFH was then quantified by measuring the remnant hexuronic acid in the supernatants (Fig. 2D) . Clearly, the different UFHs precipitate similarly in the presence of increasing concentrations of protamine, confirming the mass/mass basis of that interaction.
HBI requires more protamine than HPI to have its anticoagulant activity neutralized
The in vitro clotting assays revealed that different doses of protamine are necessary to neutralize the same anticoagulant activity (IU mg À1 ) of HPI and HBI, because of the different masses of the two heparins that are necessary to exert the same potency. To assess this difference in further detail, we investigated the protamine-neutralization profiles of these UFHs with ex vivo anti-FIIa and anti-FXa assays. In these experiments, HPI or HBI (200 IU kg
À1
) was administered intravenously to rats, and different doses of protamine were then added to the heparinized plasmas collected from the rats. Significantly higher doses (P < 0.05) of protamine were necessary to neutralize both the antiFIIa (Fig. 3A,C) and anti-FXa (Fig. 3B,D) activities of HBI (EC 50 = 0.12 lg mL À1 and EC 50 = 0.08 lg mL À1 , respectively) than those of HPI (EC 50 = 0.06 lg mL
and EC 50 = 0.05 lg mL
, respectively). These ex vivo assays show that, even after physiological interactions with components of plasma and blood vessels, HBI continues to need a higher dose of protamine than HPI to have its anticoagulant activity fully neutralized. A (Fig. 3E,F) , in which fixed amounts of the two UFHs (0.05 IU mL
) and increasing quantities of protamine were directly added to the purified proteins.
HBI needs more protamine than HPI to have its bleeding effect abolished
As seen in the in vitro and ex vivo assays, higher quantities of HBI are necessary to achieve the same anticoagulant activity as that of HPI, and thus a higher dose of protamine is necessary to neutralize HBI because of the mass/mass basis of that neutralization reaction. Considering this, we evaluated whether a similar dose of protamine could abolish the bleeding effects of HPI and HBI in an in vivo experimental model. Doses of approximately 400 IU kg À1 HBI (4 mg kg À1 ) and HPI (2 mg kg À1 ), followed or not by 4 mg kg À1 protamine, were administered intravenously to rats, and the bleeding was then measured by quantifying the blood loss through a cut in the tails of the rats [14] . Both UFHs administered alone to the rats significantly increased blood loss (P < 0.001) in comparison with saline (Fig. 4) . However, rats treated with the different UFHs and then with protamine showed different bleeding profiles (Fig. 4) , with HBI, but not HPI, exerting a significant bleeding effect (P < 0.05), even after administration of the standard dose of protamine recommended by the manufacturers to fully neutralize UFHs (1 mg of protamine neutralizes not less than 100 IU of UFH) [12, 13] . These in vivo results clearly demonstrated that, because of the higher quantity of HBI needed to achieve the same anticoagulant potency of HPI, higher doses of protamine are needed to completely eliminate the most serious side effect of heparins, i.e. hemorrhage. This became clear when inappropriate doses of protamine administered to neutralize HBI after surgical procedures in Brazilian hospitals provoked several cases of postsurgical bleeding [20, 21] . HBI and HPI interact similarly with protamine on an affinity chromatography column
After performing assessments of the pharmaceutical features of the different protamin-neutralization profiles of HBI and HPI, we carried out in-depth chemical analysis of these neutralization reactions. We began by evaluating the interactions of HPI and HBI with protamine via affinity chromatography with a column prepared with Sephadex coupled to protamine. Both HPI and HBI eluted from the column as polydisperse peaks with ⁓ 1 M NaCl (Fig. 5) . These similarities seen in the chromatograms of these different UFHs clearly demonstrate their equal interactions with protamine, in spite of the indisputable differences regarding their compositions and anionicstrengths [17] .
Protamine complexes preferentially with the most abundant and higher-sulfated chains of HBI HPI is composed of homogeneous polysaccharide chains featuring a high content of N,6-disulfated a-glucosamine units, whereas HBI has two different chains: one similar to HPI (rich in N,6-disulfated a-glucosamine) and the other enriched in N-sulfated a-glucosamine but lacking 6-sulfation [25] . We evaluated the UFH-protamine complexation reaction of HPI and HBI by analyzing, via 1D 1 H-NMR spectra, their remnants after precipitation with increasing quantities of protamine. The preponderant signals of HPI, assigned to H1 of N,6-disulfated a-glucosamine (A1) and H1 and H5 of its neighbor a-iduronic acid (I1-A and I5-A, respectively), decreased continuously and homogeneously with the addition of increasing quantities of protamine (Fig. 6A) , with a linear trend, as clearly observable through their quantification (red closed circles; Fig. 6C-E) . On the other hand, complexation of HBI operates in a more heterogeneous manner (Fig. 6B ).
Higher-sulfated chain components of HBI, enriched with N,6-disulfated a-glucosamine units featuring the signals A1, I1-A, and I5-A, also precipitated homogeneously with a linear trend (blue closed circles; Fig. 6C-E) , whereas their lower-sulfated chains, containing higher proportions of disaccharides containing N-sulfated a-glucosamine (signals C1, I1-C, and I5-C), precipitated only with higher concentrations of protamine, clearly following a polynomial trend (blue open circles; Fig. 6C-E) . Therefore, higher-sulfated chain components of HBI are preferentially removed from the solution relative to their lower-sulfated chains enriched with exclusively N-sulfated a-glucosamine. The preferential complexation of the higher-sulfated chain components of intact HBI with protamine raises a question: have protamine peptides more affinity for N,6-disulfated a-glucosamine than with the lower-sulfated N-sulfated a-glucosamine, or does the preferential complexation takes place just because of the distinct abundance of those structurally distinct chains? To answer this question, we fractionated HBI into their higher-sulfated and lower-sulfated chains by ion-exchange chromatography [25] , and then analyzed their spectra after titration with increasing concentrations of protamine. As expected, the higher-sulfated HBI fraction, which is mostly composed of N,6-disulfated a-glucosamine, precipitates homogeneously with the addition of increasing concentrations of protamine (Fig. 6F) , and its preponderant signals (A1, I1-A, and I5-A) decrease, with a linear trend (black closed circles; Fig. 6H-J) . It is noteworthy that the decrease in signals related to disaccharides containing N-sulfated a-glucosamine (C1, I1-C, and I5-C) seen in the spectra of the higher-sulfated HBI fraction (black open circles; Fig. 6H-J) followed a polynomial trend, precipitating only with higher concentrations of protamine, which clearly indicates the contamination of this fraction with minute amounts of the lower-sulfated HBI fraction. Surprisingly, both N,6-disulfated a-glucosamine and N-sulfated a-glucosamine components of the lower-sulfated HBI fraction precipitated in a continuous manner during the titration with protamine (Fig. 6G) , and their preponderant signals (A1, I1-A, and I5-A, and C1, I1-C, and I5-C, respectively) decreased with a linear trend (green circles; Fig. 6H-J) , indicating homogeneous complexation of both units. Therefore, protamine does not have a higher affinity for either N,6-disulfated or N-sulfated a-glucosamine units; instead, it complexes similarly with them when the distinct chain components of HBI are properly separated as isolated fractions.
This set of results clearly showed that protamine complexes preferentially with the more abundant fraction present in UFH mixtures containing chains with distinct sulfate contents, as demonstrated by the preferential removal of the higher-sulfated over the lower-sulfated chains present as a mixture in intact HBI preparations. However, protamine complexes on a mass/mass basis with UFH preparations containing a single type of chain, irrespective of their sulfate content, as shown by the continuous and homogeneous precipitation of HPI and the higher-sulfated and lower-sulfated fractions purified from HBI during their titrations with protamine. In conclusion, protamine preferentially removes the most abundant and higher-sulfated fraction of HBI relative to the lower-sulfated fractions, although their peptides showed similar affinity for both higher-sulfated and lower-sulfated chain components of HBI.
Different peptide components of protamine interact preferentially with the UFHs
Protamine is composed of a mixture of four preponderant peptide chains with different molecular weights and amino acid sequences [7] . We first confirmed the presence of these four peptides by using ESI-HRMS. Spectra obtained by infusing protamine alone (five infusions; Fig. 7A ) revealed the presence of one peptide (P1) with a lower molecular weight (21.2% AE 3.7%), two (P2 and P3) with similar and intermediary molecular weights (7.9% AE 1.2% and 16.8% AE 2.9%, respectively), one with a higher molecular weight (18.8% AE 3.0%), and some minor peptides (26.1% AE 6.3%, combined). To investigate whether different UFHs interact preferentially with some of these peptides, we incubated protamine with intact HPI or HBI, and then analyzed the residual protamine in the supernatant by ESI-HRMS. The mass spectra revealed that HPI and HBI interact similarly (P > 0.05) with the whole set of peptide components of protamine ( Fig. 7B-D) , showing that the structural and charge differences between these UFHs do not promote noticeable selectivity by protamine, confirming the mass/mass basis of the complexation reaction. However, when we analyzed the relative abundances of the four major peptide (P1-P4) components and of the minor peptide component of protamine before (Fig. 7D , black bars) and after interaction with HPI and HBI (Fig. 7D , red and blue bars, respectively), we observed that, irrespective of the UFH type, the abundances of P1 and P4 and of the minor peptides decreased more than those of the peptides with intermediate molecular weights, i.e. P2 and P3. Therefore, some of the peptide components of protamine have more affinity for UFHs, and are thus possibly more effective during the neutralization reaction.
Conclusions
We have demonstrated herein that protamine neutralization of UFHs operates on a mass/mass basis, as shown by the higher quantity of protamine necessary to neutralize HBI, which demands significantly higher doses than those of HPI to achieve the same anticoagulant activity. We also identified the components of these UFHs and protamine that interact preferentially with each other.
ESI-HRMS revealed that some of the peptide components of protamine have higher affinity for UFH, irrespective of its animal origin. Analyses with 1D 1 H-NMR of HPI subjected to increasing concentrations of protamine revealed a linear regression dependence, without selection of a particular fraction with a distinct structure. Otherwise, intact HBI has a heterogeneous protaminecomplexation profile, as demonstrated by the polynomial regression of the chains enriched with N-sulfated a-glucosamine, which were removed from the solution only with higher concentrations of protamine. On the other hand, fractions with higher and lower sulfate contents purified from HBI showed similar protamine-complexation profiles despite their indisputable compositional differences. This set of results clearly indicate that protamine preferentially removes the most abundant UFH chain present in intact HBI, i.e. the higher-sulfated fraction, relative to the minor component with a a low sulfate content.
In addition to the conceptual aspect revealed by our study concerning the chemical mechanism of protamine neutralization of UFHs from different animal sources, our results have considerable practical implications. The current protocols for protamine neutralization of UFHs after procedures involving extracorporeal circulation are based on monitoring the anticoagulant state of the patients [29, 30] , which can effectively evaluate the removal of HPI and the fraction of HBI with a high sulfate content. However, the fraction with a low sulfate content, which accounts for ⁓ 40% of the pharmaceutical preparations of HBI [29] , could be not detected, because of its low anticoagulant activity. Elucidating the possible deleterious effects of the low-anticoagulant fraction component of HBI, which could remain in the circulation after protamine-neutralization procedures monitored exclusively by point-of-care assessments of the anticoagulant state of patients, is essential to improve the safety of this UFH and hence avoid bleeding incidents such as those experienced in Brazil [20, 21] . 
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